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Worldwide an estimated 42 million people are living
with HIV/AIDS and more than 20 million people have
already died of AIDS.1 More than 95% of all new HIV
infections are in developing countries, making
HIV/AIDS among the most serious threats not only to
global health, but to global development. It is now
widely accepted that an effective, protective HIV vac-
cine would provide the best method for controlling the
catastrophic HIV/AIDS pandemic, especially in less
developed countries.2,3
Clinical trials of HIV vaccines have been under way for
more than 15 years but the first phase III efficacy trial
was completed only recently. Vaccine development
and assessment have primarily taken place in
developed, Western countries and most early-
phase human clinical trials have been done in
the USA and Europe. Globally, there have
been more than 80 phase I and II trials but
only one product – a bivalent, recombinant
gp120 vaccine, AIDSVAX – has reached large-
scale phase III efficacy testing in North
America, The Netherlands and Thailand.
Despite many years of research, most of the
experimental vaccines are still limited to test-
ing in animal models and no efficacious HIV
vaccine for humans has yet been identified.
A wide variety of vaccine approaches are cur-
rently being pursued. For many years the vac-
cine pipeline was limited to monomeric gp120
or gp160 proteins based on laboratory strains
of the virus, different synthetic peptides and
simple poxvirus-HIV-1 recombinant vectors.
This has recently expanded to include gp120
constructs based on clinical isolates of HIV-1,
conformational envelope antigens, complex
canarypox vectors expressing multiple HIV-1
genes, different constructs of naked DNA vac-
cines, new live vectors, including the modified
vaccinia Ankara (MVA), and the Venezuelan
equine encephalitis virus replicon. Vaccine
classes and types are summarised in Table I.4
The ability of a vaccine or a component of a
micro-organism to stimulate an immune
response is key to memory in the immune
response for future protection.  Designing a
successful vaccine against HIV has been ham-
pered by the lack of an immune correlate of
protection, i.e. it is not clear which type of
immune response is needed to provide pro-
tection against HIV. Unfortunately, animal pro-
tection experiments and natural history
studies have failed to produce conclusive results and
no animal model proposed so far can adequately mimic
human disease infection and disease progression.5
CELLULAR IMMUNE RESPONSES
Cytotoxic T-lymphocytes (CTLs) are part of the cellular
immune response and are associated with control of
viral replication. CTLs are capable of directly destroying
HIV-infected cells. Therefore vaccines designed to
stimulate CTL responses are more likely to lead to con-
trol of viral replication, and thus viral load, as opposed
to creating sterilising immunity which would prevent
primary HIV infection. A subset of T-lymphocytes
(CD8+ T cells) have CD8 receptors on their surfaces
and are the dominant effector cells responsible for
defending the host against cellular level viral infections.
Other CD8+ T cells are capable of suppressing HIV
replication without necessarily killing the infected cell.
CD8+ T cells may be critical to resisting HIV infection.
A further component of cellular immunity includes the
regulatory T cells which are capable of directing anti-
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Table I. HIV vaccine classes and types
Class Product name Producer
1. Canarypox ALVAC vCP 1452 Aventis Pasteur
vectors 








3. Fowlpox vectors TBC-F357; Therion
TBC-F349
4. Lipopeptides LIPO-5 Aventis Pasteur/ 
ANRS
5. Modified MVA pGA/JS2 NIAID-LVD
Vaccinia TBC-M358 Therion
Ankara vectors TBC-M335 Therion
6. Non-replicating MRKAd5 HIV-1 Gag Merck
adenovirus VRC-HIVDNA-010 NIH VRC
vectors
7. Peptides Wyeth me CTL peptide Wyeth
vaccine
8. Proteins AIDSVAX B/B VaxGen
gp120 MN VaxGen
TBD - Clade C Env subunit Chiron
gp140 SF-162 — oligomeric Chiron
V2-deleted
NefTat + gp120W61D GlaxoSmithKline 
9. VEE vectors AVX-101 AlphaVax 
10. Yeast vectors HIVAX-GS GlobeImmune
11. Live attenuated VSV Wyeth
vector
Source: The Pipeline Project. HIV vaccines in development. 4
body- and cell-mediated immune responses. The main
regulatory T cell, the helper T cell or CD4+ T cell, is also
HIV’s main target. 
CD4+ T helper function is typically measured by mea-
suring T-cell proliferation following incubation with viral
antigens. Most HIV-infected subjects have weak or
undetectable proliferative responses to HIV antigens.6
Monitoring of cellular immune response to vaccination
has advanced significantly in the last few years; the
more complex chromium release assay has been
superseded by new assays that allow a rapid identifica-
tion of T-cell responses. Specifically, the gamma-inter-
feron enzyme linked immunospot (Elispot) assay and
the intracytoplasmic cytokine (ICC) assay are now
being commonly utilised worldwide to measure T-cell
functional response to HIV-1.
The failure of vaccinated or infected subjects to devel-
op virus-specific proliferative responses is common
and may result from infection and subsequent death of
HIV-specific CD4+ T cells when they encounter an HIV-
infected antigen-presenting cell. Relatively vigorous
HIV-1-specific CD4+ T helper responses have been
reported in HIV-infected long-term non-progressors and
patients who received potent antiretroviral therapy
early in the course of primary infection.7 Induction of
strong HIV-specific proliferative responses may there-
fore be an important goal for candidate vaccines,
although there is at present no definitive evidence for
this conclusion. 
HUMORAL IMMUNE RESPONSES
Humoral (antibody-mediated) immunity refers to pro-
tection provided by antibodies, the secreted products
of B-lymphocytes. Antibodies are important because
they are the immune system’s first line of defence and
are thought to be the key to preventing viruses from
ever contacting the cells they infect.
Antibodies function by either binding to part of the virus
which may or may not have antiviral effects (binding
antibodies) or are capable of inactivating or preventing
the virus from infecting cells (neutralising antibodies).
Finding ways to induce the production of antibodies
able to neutralise HIV has proved difficult. These diffi-
culties have arisen because HIV has the ability to
mutate at a rapid rate8 and several clades of the virus
exist.9
Gp160, a protein located in the outer envelope of HIV,
has been identified as important for stimulating neu-
tralising antibodies. However, several features of the
HIV-1 envelope, e.g. glycosylation and the oligomeric
form, limit its ability to be neutralised by antibodies.10 
A variety of different assays have been used to charac-
terise humoral responses against HIV, including binding
to viral proteins (as assessed by either ELISA or
Western blot), inhibition of syncytia formation, comple-
ment fixation, ability to mediate antibody-dependent
cell-mediated cytotoxicity (ADCC), ability to neutralise
infectivity or cell fusion, and ability to block CD4-gp120
interactions. At present, whether any of these assays is
more likely than another to measure antibody respons-
es relevant to protective immunity is unknown.11
Current HIV candidates elicit reasonably potent cellular
immune responses, but only low levels of neutralising
antibodies. Such CTL-based vaccines (e.g. DNA vac-
cines) do not prevent infection, but can have a benefi-
cial effect on disease course. A combination of both
humoral and cell-mediated immune responses may be
needed for effective protection.3
MUCOSAL IMMUNE RESPONSES
In addition to cellular and humoral immune responses,
the stimulation of mucosal immunity may also be nec-
essary to achieve protection against HIV. The majority
of HIV infections occur via mucosal routes and stimu-
lating the mucous membranes that line the rectal and
genital tract to induce mucosal immunity may be an
essential requirement of an effective HIV vaccine. 
Induction of protective immunity against mucosal chal-
lenge with SIV or SHIV has been reported in several
macaque models.12,13 Although these animal model
results cannot be assumed to hold true for humans
exposed to HIV, there is evidence from studies on high-
ly exposed persistently seronegative (HEPS) individuals
that mucosal immune responses are possible.14,15
THE PRIME-BOOST STRATEGY
One way to enhance immune responses to HIV, which
is currently in vogue, is the combination approach
called prime-boost strategy. This strategy endeavours
to get the immune system to make both neutralising
antibodies and to launch a strong cell-mediated
response. The immune system is first primed with one
vaccine, e.g. naked DNA, and then boosted with a dif-
ferent vaccine, e.g. live vector/protein.5
By itself, a naked DNA vaccine stimulates production of
memory T cells but few antibodies. The prime-boost
combination, however, can stimulate a strong cellular
immune response, including persistent killer CD8+ T
cells as well as antibodies that neutralise the virus. The
prime-boost method has shown promise in animal
models and better protection has been achieved using
this method than any other HIV vaccine strategy to
date. This strategy has also been tested in human clin-
ical phase I and II trials, where it has been found to be
safe and effective. 
IMPLICATIONS OF THE VaxGen TRIAL
RESULTS
The results of the first phase III AIDS vaccine (AIDSVAX
B/B) trial were announced in February 2003. Although
safe, the vaccine did not show an overall reduction of
HIV infection in the vaccination arm of the entire study
population.16 These results suggest that narrowly
defined antibodies are not effective in providing pro-
tection against HIV infection.  
Protein-based vaccines, such as AIDSVAX B/B, gener-
ally elicit only a humoral response, without significant
stimulation of the cellular arm of the immune system.
The reasons the vaccine was not successful may be
either that the antibodies generated by the vaccine did
not coincide with the antigens on the viruses which led
to infection in the study population or that the antibod-
ies on their own were not sufficient to protect against
HIV infection. More phase III trials are needed to better
understand this.
CONCLUSION
The HIV vaccine pipeline includes many types of candi-
date and specific epitope vaccines that are being devel-
oped in parallel.  Despite significant advances in AIDS
vaccine research, considerable challenges remain.  The
AIDS vaccine research field will move forward with fur-
ther phase III efficacy trials.  An AIDS vaccine remains
an important hope for the control of HIV/AIDS, but its
realisation is still several years away.  
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